Evidence map›Paper›PMID 36902734›Full record

ReviewJournal of clinical medicine2023

Gut Microbiota in Chronic Kidney Disease: From Composition to Modulation towards Better Outcomes-A Systematic Review.

Luminita Voroneanu, Alexandru Burlacu, Crischentian Brinza, Andreea Covic, Gheorghe G Balan, Ionut Nistor, Cristina Popa, Simona Hogas, Adrian Covic

Registry-linked trialFull text readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07483697 (Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People), which is not on this map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07483697 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People: a Prospective Study

TypeinterventionalSponsorCentenario Hospital Miguel HidalgoRan2026 to 2026Enrolled200ConditionsExercise, Diet Interventions, Symbiotic, CKD Stage 1Armssymbiotic, Placebo
3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Gut-kidney axis: Dysbiosis and renal disease.World journal of nephrology · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. A guide to uraemic toxicity.Nature reviews. Nephrology · 2026
    Review
  14. Characterization of gut microbiota in patients with diabetic kidney disease.Frontiers in cellular and infection microbiology · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luminita VoroneanuNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, 700503 Iasi, Romania.
Alexandru BurlacuFaculty of Medicine, 'Grigore T. Popa' University of Medicine, 700115 Iasi, Romania.ORCID 0000-0002-3424-1588
Crischentian BrinzaFaculty of Medicine, 'Grigore T. Popa' University of Medicine, 700115 Iasi, Romania.ORCID 0000-0002-6253-3203
Andreea CovicNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, 700503 Iasi, Romania.
Gheorghe G BalanFaculty of Medicine, 'Grigore T. Popa' University of Medicine, 700115 Iasi, Romania.ORCID 0000-0002-2919-4940
Ionut NistorNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, 700503 Iasi, Romania.
Cristina PopaFaculty of Medicine, 'Grigore T. Popa' University of Medicine, 700115 Iasi, Romania.
Simona HogasNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, 700503 Iasi, Romania.
Adrian CovicNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, 700503 Iasi, Romania.ORCID 0000-0002-9985-2486

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA bidirectional kidney-gut axis was described in patients with chronic kidney disease (CKD). On the one hand, gut dysbiosis could promote CKD progression, but on the other hand, studies reported specific gut microbiota alterations linked to CKD. Therefore, we aimed to systematically review the literature on gut microbiota composition in CKD patients, including those with advanced CKD stages and end-stage kidney disease (ESKD), possibilities to shift gut microbiota, and its impact on clinical outcomes. MATERIALS AND

methodsWe performed a literature search in MEDLINE, Embase, Scopus, and Cochrane databases to find eligible studies using pre-specified keywords. Additionally, key inclusion and exclusion criteria were pre-defined to guide the eligibility assessment.

resultsWe retrieved 69 eligible studies which met all inclusion criteria and were analyzed in the present systematic review. Microbiota diversity was decreased in CKD patients as compared to healthy individuals. Ruminococcus and Roseburia had good power to discriminate between CKD patients and healthy controls (AUC = 0.771 and AUC = 0.803, respectively). Roseburia abundance was consistently decreased in CKD patients, especially in those with ESKD (

conclusionsPatients with CKD had an altered gut microbiome profile, even at early disease stages. Different abundance at genera and species levels could be used in clinical models to discriminate between healthy individuals and patients with CKD. ESKD patients with an increased mortality risk could be identified through gut microbiota analysis. Modulation therapy studies are warranted.

Indexed as

chronic kidney diseaseend-stage kidney diseasegut dysbiosisgut microbiotahemodialysismortalityoutcomes

Identifiers

PMID36902734
PMCPMC10003930

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read5
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.